Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 9/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclazocine SCHEMBL29373974 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL12014006 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL13936390 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL16746611 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL16557078 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL12013221 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL13014951 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL20820911 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL20505563 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR | |
| Cyclazocine SCHEMBL29424671 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5424 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2025006982-A1 | POTENT AND SELECTIVE DOPAMINE D3 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-02 | — | — | WO | claimed |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | claimed |
| US-20240390490-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-11-28 | — | — | US | claimed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | claimed |
| WO-2024079072-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | BIODOL THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | claimed |
| EP-4353712-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2024-04-17 | — | — | EP | claimed |
| US-4692451-A | ADMINISTERING NARCOTIC ANTAGONIST | TRUSTEES OF TUFTS COLLEGE (US) | 1987-09-08 | — | — | US | claimed |
| US-4622244-A | SOLIDIFICATION | THE WASHINGTON UNIVERSITY (US) | 1986-11-11 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| US-4473640-A | OF DRUG-GLUCURONIC ACID COMPLEXES | COMBIE JOAN D | 1984-09-25 | — | — | US | claimed |
| US-4464378-A | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-08-07 | — | — | US | claimed |
| US-4434168-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-02-28 | — | — | US | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| US-4267182-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-05-12 | — | — | US | claimed |
| US-4029798-A | SYNERGISTIC MIXTURE OF INDOLE-3-ACETIC ACID DERIVATIVE AND NARCOTIC | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-06-14 | — | — | US | claimed |